Everything You Wanted to Know About Ketamine, But Were Afraid to Ask

Ketamine is having a moment in the news (erm… Musk), but for decades ketamine was that weird drug they used in emergency rooms and sometimes for horses. A dissociative anesthetic. A party drug for people looking to check out. But now? It’s the shiny new thing in mental health, promising rapid relief for depression, a condition that’s frankly, a brutal, slow grind for millions. This isn’t your grandmother’s Prozac. This is fast, powerful, and comes with a whole new set of questions.

The Rebrand: From Anesthetic to Antidepressant

Ketamine, first synthesized in 1962, has a long history as a general anesthetic and has been on the World Health Organization’s Essential Medications List since 1985. It’s known for producing a “dissociative” state, where patients feel disconnected from their body, while still maintaining essential functions like breathing. In the early 1970s, it started popping up as a recreational drug, known on the street by names like “Special K”.

Fast forward, and a breakthrough happened: studies showed that a single low dose, well below what you’d use for anesthesia, could rapidly improve depressive symptoms within a day. This wasn’t weeks or months like traditional antidepressants, this was hours or days. This rapid effect has made it a significant point of interest, especially for severe and treatment-resistant depression (TRD), and even for managing acute suicidal ideation. In 2019, ‘esketamine,’ one form of ketamine, even got the green light from the FDA as an add-on treatment for TRD. This marked a “new era” in neuropsychiatric therapeutics.

The Science, Simplified: How it (Might) Work

 At its core, ketamine blocks a specific receptor in the brain, which somehow, in a way researchers are still trying to fully grasp, leads to profound antidepressant effects. It’s a paradigm shift in how we think about treating neuropsychiatric disorders.

There’s also a lot of buzz about its metabolites, the substances ketamine turns into after your body processes it. Some evidence suggests these metabolites might be doing a lot of the heavy lifting for the antidepressant effect, possibly even without some of the unwanted dissociative side effects. There’s also some debate about whether the opioid system is involved in its antidepressant actions, with some studies suggesting it is, and others disputing a direct role. The reality is, it’s complex, and they’re still figuring it out.

The Twins: (S)-Ketamine vs. (R)-Ketamine

Ketamine itself is what’s called a “racemic mixture,” meaning it’s composed of two mirror-image molecules: (S)-ketamine (also known as esketamine) and (R)-ketamine (or arketamine). It’s like having two different keys that fit the same lock, but unlock different doors, or perhaps open the same door with different levels of ease and additional effects.

Esketamine, the (S)-enantiomer, is the one that got FDA approval for treatment-resistant depression via a nasal spray. Studies show it can be effective in this form. In preclinical models, (R)-ketamine has actually shown greater antidepressant efficacy than (S)-ketamine. Early human trials for (R)-ketamine hinted at promising antidepressant effects with fewer dissociative symptoms. However, larger trials have not yet established its significant antidepressant effect, suggesting more research is needed.

Here’s the kicker: in animal models, the (S)-enantiomer (esketamine) shows a higher potential for abuse liability compared to the (R)-enantiomer. This divergence in properties between the two forms is a big deal for future drug development and understanding the full picture of ketamine’s therapeutic and adverse effects.

The Catch: Side Effects and Abuse Risks

No free lunch, right? While therapeutic doses for depression are lower than anesthetic ones, side effects are still a reality. During or shortly after administration, patients might experience dissociative symptoms, a feeling of detachment from reality, or being “out of body”. There can also be increases in blood pressure (hypertension) and heart rate (tachycardia), as well as palpitations, nausea, and dizziness. These effects are generally short-lived and tolerable at therapeutic doses.

The bigger dark cloud hangs over its abuse potential. Ketamine has been a popular recreational drug since the 1970s, often associated with dance culture. Users might seek the “K-hole” experience, a state of profound dissociation and unresponsiveness. The risk for misuse and diversion is real, and it can lead to addiction.

Beyond the acute “trip,” chronic recreational use is associated with serious long-term problems. We’re talking about severe bladder issues (cystitis), which can be debilitating and cause frequent urination and pain. There’s also the risk of cholangiopathy, a disease affecting the bile ducts of the liver. And don’t forget the brain: chronic use can lead to impaired cognitive function, including memory and verbal processing issues. While clinical use might have lower abuse potential than stimulants or opioids, the fact remains that it exists.

The Bottom Line: Caution

Ketamine is a powerful drug that has genuinely revolutionized the treatment landscape for severe depression, offering hope where traditional treatments fall short. Its rapid action is a game-changer, especially for patients with suicidal ideation. However, this isn’t something you pick up at your local pharmacy. It requires strict medical supervision and is typically administered only in clinical settings capable of monitoring patients and providing immediate care if needed. The use of racemic ketamine via oral or other non-IV routes is generally limited to specialists due to less evidence and higher risks of misuse. Research continues to explore its full potential, including for conditions like anxiety, substance use disorders, and chronic pain, but the clear message is that while promising, ketamine is a tool that demands respect and rigorous oversight. The market for depression treatments is huge, and ketamine has carved out a niche, but it’s a niche that comes with significant guardrails for a reason.

Sources consulted:

Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., … & Michaelides, M. (2021). Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Molecular psychiatry, 26(11), 6704-6722.

Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022). Mechanisms of ketamine and its metabolites as antidepressants. Biochemical pharmacology, 197, 114892.

Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate Jr, C. A. (2024). Ketamine in neuropsychiatric disorders: an update. Neuropsychopharmacology, 49(1), 23-40.

Nikolin, S., Rodgers, A., Schwaab, A., Bahji, A., Zarate, C., Vazquez, G., & Loo, C. (2023). Ketamine for the treatment of major depression: a systematic review and meta-analysis. EClinicalMedicine, 62.

Schep, L. J., Slaughter, R. J., Watts, M., Mackenzie, E., & Gee, P. (2023). The clinical toxicology of ketamine. Clinical Toxicology, 61(6), 415-428.

Smith-Apeldoorn, S. Y., Veraart, J. K., Spijker, J., Kamphuis, J., & Schoevers, R. A. (2022). Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. The Lancet Psychiatry, 9(11), 907-921.

Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate Jr, C. A. (2022). Ketamine treatment for depression: a review. Discover mental health, 2(1), 9.